nach oben

Erschienen in:

13.08.2019 | Original Research

CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients

verfasst von: Shirin Eyvazi, Amir Mahdi Khamaneh, Vahideh Tarhriz, Mojgan Bandehpour, Mohammad Saeid Hejazi, Amir Taher Eftekhar Sadat, Bita Sepehri

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastric cancer is an aggressive disease which is the fourth prevalent malignancy in the world. Beside the genetic factors, epigenetic alterations such as promoter CpG island hyper methylation are involved in the emergence of gastric cancer. Herein, we investigated the methylation status of CDH11, EphA5, and HS3ST2 genes in patients with and without gastric adenocarcinoma for the first time.

Methods

In the study 40 paraffin-embedded tissue sections from gastric adenocarcinoma patients and 40 specimens from patients with functional dyspepsia were taken. DNA extraction was performed using a modified salting out method. Epizen DNA methylation kit was used to the bisulfite DNA conversion. The methylation status of CDH11, EphA5, and HS3ST2 genes were analyzed by methylation-specific PCR (MSP) technique.

Results

Among the 80 specimens, 71 DNA samples were achieved (34 gastric adenocarcinoma patients and 37 control patients). The results showed that CDH11, EphA5, and HS3ST2 genes are methylated in 28 (82.45%), 19 (55.88%), and 26 (76.47%) of 34 DNA samples from gastric adenocarcinoma patients, respectively, whereas, these genes are methylated in 7 (18.91%), 9 (24.32%) and 7 (18.91%) of 37 samples from noncancerous patients, respectively. Statistical analyses using a chi-squared test showed that there is a statistically significant difference in methylation level of CDH11, EphA5, and HS3ST2 genes between gastric cancer and uncancerous patients (p < 0.05).

Conclusion

To the best of our knowledge, this is the first report on methylation of CDH11, EphA5, and HS3ST2 promoters’ in gastric adenocarcinoma patients using MSP. Identification of novel cancer-related molecular mechanisms can be useful in detection of new treatment strategies.

Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–48.PubMedPubMedCentralCrossRef

Rugge M, Fassan M, Graham DY. Epidemiology of gastric cancer. In: Gastric cancer: Springer; 2015. p. 23–34.

Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.PubMedCrossRef

Patel TN, Roy S, Ravi R. Gastric cancer and related epigenetic alterations. Ecancermedicalscience. 2017:11.

Takeshima H, Yamada H, Ushijima T. Cancer epigenetics: aberrant DNA methylation in cancer diagnosis and treatment. In: Oncogenomics: Elsevier; 2019. p. 65–76.

Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. In: Cancer epigenetics: Springer; 2015. p. 3–25.

Li S, Zhu Y, Zhi L, Han X, Shen J, Liu Y, et al. DNA methylation variation trends during the embryonic development of chicken. PLoS One. 2016;11(7):e0159230.PubMedPubMedCentralCrossRef

Lim DH, Maher ER. DNA methylation: a form of epigenetic control of gene expression. Obstet Gynaecol. 2010;12(1):37–42.

Du J, Johnson LM, Jacobsen SE, Patel DJ. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015;16(9):519–32.PubMedPubMedCentralCrossRef

10.

Tahara T, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer. Epigenomics. 2015;7(3):475–86.PubMedCrossRef

11.

Li L, Ying J, Li H, Zhang Y, Shu X, Fan Y, et al. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas. Oncogene. 2012;31(34):3901–12.PubMedCrossRef

12.

Carmona FJ, Villanueva A, Vidal A, Munoz C, Puertas S, Penin RM, et al. Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol. 2012;228(2):230–40.PubMedPubMedCentralCrossRef

13.

Yuan S, Li L, Xiang S, Jia H, Luo T. Cadherin-11 is inactivated due to promoter methylation and functions in colorectal cancer as a tumour suppressor. Cancer Manag Res. 2019;11:2517–29.PubMedPubMedCentralCrossRef

14.

Lin YL, Gui SL, Ma JG. Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer. Oncol Lett. 2015;10(2):647–52.PubMedPubMedCentralCrossRef

15.

Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165–80.PubMedPubMedCentralCrossRef

16.

Chen X, Wang X, Wei X, Wang J. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma. J Ovarian Res. 2016;9(1):83.PubMedPubMedCentralCrossRef

17.

Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, et al. Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer. 2015;15(1):18.PubMedPubMedCentralCrossRef

18.

Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One. 2011;6(9):e24426.PubMedPubMedCentralCrossRef

19.

Hwang J-A, Kim Y, Hong S-H, Lee J, Cho YG, Han J-Y, et al. Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis. PLoS One. 2013;8(11):e79634.PubMedPubMedCentralCrossRef

20.

Vijaya Kumar A, Salem Gassar E, Spillmann D, Stock C, Sen YP, Zhang T, et al. HS3ST2 modulates breast cancer cell invasiveness via MAP kinase-and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression. Int J Cancer. 2014;135(11):2579–92.PubMedCrossRef

21.

Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene. 2003;22(2):274–80.PubMedCrossRef

22.

Lim EH, Ng SL, Li JL, Chang AR, Ng J, Ilancheran A, et al. Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy. Gynecol Oncol. 2010;119(2):225–31.PubMedCrossRef

23.

Leontiou CA, Hadjidaniel MD, Mina P, Antoniou P, Ioannides M, Patsalis PC. Bisulfite conversion of DNA: performance comparison of different kits and methylation quantitation of epigenetic biomarkers that have the potential to be used in non-invasive prenatal testing. PLoS One. 2015;10(8):e0135058.PubMedPubMedCentralCrossRef

24.

Organization WH. Global cancer rates could increase by 50% to 15 million by 2020. In: Global cancer rates could increase by 50% to 15 million by 2020; 2003.

25.

Ferreira HJ, Esteller M. CpG islands in cancer: heads, tails, and sides. In: CpG Islands: Springer; 2018. p. 49–80.

26.

Wang X, Xu H, Wu Z, Chen X, Wang J. Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in cc RCC. Int J Exp Pathol. 2017;98(1):34–9.PubMedPubMedCentralCrossRef

27.

Sun B, Wu J, Zhang T, Wang C. High-resolution analysis of genomic profiles of hepatocellular carcinoma cells with differential osteopontin expression. Cancer Biol Ther. 2008;7(3):387–91.PubMedCrossRef

28.

Wu J-C, Sun B-S, Ren N, Ye Q-H, Qin L-X. Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J Cancer Res Clin Oncol. 2010;136(4):595–601.PubMedCrossRef

Titel: CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients
verfasst von: Shirin Eyvazi
Amir Mahdi Khamaneh
Vahideh Tarhriz
Mojgan Bandehpour
Mohammad Saeid Hejazi
Amir Taher Eftekhar Sadat
Bita Sepehri
Publikationsdatum: 13.08.2019
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-019-00290-1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients